For the procurement of COVID-19 vaccines, a supply order dated January 11 was placed with the Serum Institute of India after Covishield was approved for restricted use in emergency situation by India's drug regulator, the Rajya Sabha was informed on Tuesday.
Union Minister of State for Health Ashwini Choubey was responding to a question on whether the government has finalised a pricing and supply agreement with the Serum Institute of India Limited for COVID-19 vaccines.
Covishield is being manufactured by the Pune-based firm with technology transfer from AstraZeneca/Oxford University.
On whether it is a fact that multiple doses of the vaccine produced for India could not be rolled out despite approval due to the lack of a formal agreement for supply, Choubey, in a written reply, said, " No. As per protocol, the supply order for COVID-19 vaccines, specifying the number of vaccine doses, was placed with the manufacturer and vaccines were delivered within 3 days to the states and UTs and other consignee points.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)